143 related articles for article (PubMed ID: 33006583)
1. Chimeric antigen receptor natural killer cells for the treatment of patients with B-cell malignancies.
Rezvani K
Clin Adv Hematol Oncol; 2020 Sep; 18(9):543-545. PubMed ID: 33006583
[No Abstract] [Full Text] [Related]
2. Eradication of established B-cell lymphoma by CD19-specific murine T cells is dependent on host lymphopenic environment and can be mediated by CD4+ and CD8+ T cells.
Cheadle EJ; Hawkins RE; Batha H; Rothwell DG; Ashton G; Gilham DE
J Immunother; 2009 Apr; 32(3):207-18. PubMed ID: 19242379
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis.
Grigor EJM; Fergusson DA; Haggar F; Kekre N; Atkins H; Shorr R; Holt RA; Hutton B; Ramsay T; Seftel M; Jonker D; Daugaard M; Thavorn K; Presseau J; Lalu MM
BMJ Open; 2017 Dec; 7(12):e019321. PubMed ID: 29288188
[TBL] [Abstract][Full Text] [Related]
4. Progress in the curative treatment of childhood hematologic malignancies.
Wayne AS; Reaman GH; Helman LJ
J Natl Cancer Inst; 2008 Sep; 100(18):1271-3. PubMed ID: 18780861
[No Abstract] [Full Text] [Related]
5. Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies.
Cooper ML; DiPersio JF
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101097. PubMed ID: 31779968
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials.
Zhu Y; Tan Y; Ou R; Zhong Q; Zheng L; Du Y; Zhang Q; Huang J
Eur J Haematol; 2016 Apr; 96(4):389-96. PubMed ID: 26115358
[TBL] [Abstract][Full Text] [Related]
7. Regulatory T-cell depletion in donor lymphocyte infusions for haematological malignancies: long-term outcomes from a prospective study.
Maury S; Redjoul R; Cabanne L; Vigouroux S; Legros L; Cohen JL
Br J Haematol; 2014 Aug; 166(3):452-5. PubMed ID: 24661112
[No Abstract] [Full Text] [Related]
8. Specific Adoptive Cellular Immunotherapy in Allogeneic Stem Cell Transplantation.
Audehm S; Krackhardt AM
Oncol Res Treat; 2017; 40(11):691-696. PubMed ID: 29069663
[TBL] [Abstract][Full Text] [Related]
9. [Cellular immunotherapy for hematopoietic malignancies].
Yasukawa M
Nihon Rinsho; 2007 Jan; 65 Suppl 1():390-4. PubMed ID: 17474435
[No Abstract] [Full Text] [Related]
10. An integrated flow cytometry analysis of 286 mature B cell neoplasms identifies CD13 as a useful marker for diagnostic subtyping.
Lau H; Nagy A; Atwater SK; Cascio MJ; Ohgami RS
Int J Lab Hematol; 2018 Dec; 40(6):715-720. PubMed ID: 30066366
[TBL] [Abstract][Full Text] [Related]
11. Idiotypic vaccination in B-cell malignancies.
Bianchi A; Massaia M
Mol Med Today; 1997 Oct; 3(10):435-41. PubMed ID: 9358470
[TBL] [Abstract][Full Text] [Related]
12. Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies.
Perales MA; Sauter CS; Armand P
Biol Blood Marrow Transplant; 2016 Jan; 22(1):17-22. PubMed ID: 26485445
[TBL] [Abstract][Full Text] [Related]
13. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
Sharma P; King GT; Shinde SS; Purev E; Jimeno A
Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
[TBL] [Abstract][Full Text] [Related]
14. Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies.
Song W; Zhang M
Clin Immunol; 2020 May; 214():108382. PubMed ID: 32169439
[TBL] [Abstract][Full Text] [Related]
15. Influence of melphalan plus fludarabine-conditioning regimen in elderly patients aged ⩾55 years with hematological malignancies.
Miyao K; Sawa M; Kuwatsuka Y; Ozawa Y; Kato T; Kohno A; Sao H; Nishida T; Iida H; Naito K; Tsurumi H; Taji H; Mizuta S; Kusumoto S; Nakase K; Morishita Y; Kawashima N; Miyamura K; Murata M;
Bone Marrow Transplant; 2016 Jan; 51(1):157-60. PubMed ID: 26437064
[No Abstract] [Full Text] [Related]
16. Chimeric antigen receptor T cell treatment in hematologic malignancies.
Goker H; Malkan UY; Demiroglu H; Buyukasik Y
Transfus Apher Sci; 2016 Feb; 54(1):35-40. PubMed ID: 26874466
[TBL] [Abstract][Full Text] [Related]
17. Sequential treatment with aT19 cells generates memory CAR-T cells and prolongs the lifespan of Raji-B-NDG mice.
Chen R; Wang M; Liu Q; Wu J; Huang W; Li X; Du B; Xu Q; Duan J; Jiao S; Lee HS; Jung NC; Lee JH; Wang Y; Wang Y
Cancer Lett; 2020 Jan; 469():162-172. PubMed ID: 31634527
[TBL] [Abstract][Full Text] [Related]
18. Clearance of Hematologic Malignancies by Allogeneic Cytokine-Induced Killer Cell or Donor Lymphocyte Infusions.
Merker M; Salzmann-Manrique E; Katzki V; Huenecke S; Bremm M; Bakhtiar S; Willasch A; Jarisch A; Soerensen J; Schulz A; Meisel R; Bug G; Bonig H; Klingebiel T; Bader P; Rettinger E
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1281-1292. PubMed ID: 30878607
[TBL] [Abstract][Full Text] [Related]
19. [Chimeric antigen receptor T-cell therapy for hematological malignancies].
Nakazawa Y
Rinsho Ketsueki; 2019; 60(9):1351-1357. PubMed ID: 31597863
[TBL] [Abstract][Full Text] [Related]
20. Autologous stem cell transplantation in hematological malignancies.
Gorin NC
Springer Semin Immunopathol; 2004 Nov; 26(1-2):3-30. PubMed ID: 15480668
[No Abstract] [Full Text] [Related]
[Next] [New Search]
